# A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive 

Source: https://onco.cc/trials/nct06445400/  
OnCo record `nct06445400` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab brengitecan, Pertuzumab, Docetaxel in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT06445400 by Sichuan Baili Pharmaceutical Co., Ltd., with 83 participants enrolled, started 2024-06-19 and due to reach its primary completion in 2025-07-21. Interventions recorded: BL-M07D1, Pertuzumab, Docetaxel. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06445400
- Phase: 2
- Setting: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT06445400: https://clinicaltrials.gov/study/NCT06445400

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06445400.json